Skip to main content

Table 2 Frequency of patients with CIN 1 and HPV-16 infection and normal donors who had serum titers of antibodies with neutralizing activity to VLPs.

From: A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection

 

SERA

ANTIGENS

CIN 1 PATIENTS HPV-16+

NORMAL DONORS

 

6/30 (1:100)

 

gVLP

3/30 (1:200)

6/30 (1:100)

 

3/30 (1:400)

 
 

Total 12/30

 
 

5/30 (1:100)

 

VLP-L1

4/30 (1:200)

4/30 (1:100)

 

2/30 (1:400)

 
 

Total 11/30

 
 

5/30 (1:100)

 

cVLP

4/30 (1:200)

4/30 (1:100)

 

2/30 (1:400)

 
 

Total 11/30

 
  1. Shown are results of hemagglutination inhibition assay (HIA) was performed to measure titers of antibodies with neutralizing activity for specific VLP particles in sera from women without evidence of HPV infection (normal) and in sera from patients with CIN 1 and HPV-16 infection. Serum from each person was assayed at various dilutions as described in the Materials and Methods. Frequencies of patients and titers of antibodies with neutralizing activity (in parentheses) for gVLPs, VLPs, and cVLPs are shown.
Back to article page

Virology Journal

ISSN: 1743-422X